Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 176Neoplasms 173Carcinoma, Non-Small-Cell Lung 152Prostatic Neoplasms 108Colorectal Neoplasms 105Lung Neoplasms 91Ovarian Neoplasms 82Neoplasm Metastasis 76Multiple Myeloma 72Pancreatic Neoplasms 70Leukemia, Myeloid, Acute 63Endometrial Neoplasms 49Squamous Cell Carcinoma of Head and Neck 47Stomach Neoplasms 45Melanoma 44Lymphoma 44Glioblastoma 42Carcinoma, Renal Cell 42Recurrence 41Brain Neoplasms 41Urinary Bladder Neoplasms 39Carcinoma, Hepatocellular 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Sarcoma 37Glioma 36Lymphoma, Non-Hodgkin 35Hematologic Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 34Esophageal Neoplasms 33Small Cell Lung Carcinoma 31

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × 30 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡